Moussa  Moïse DIAGNE

Dr. Moussa Moïse DIAGNE

Institut Pasteur de Dakar
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
AKAlpha Keita
Alpha Keita
FKFara R Koundouno
Fara R Koundouno
MFMartin Faye
Martin Faye
ADAriane Düx
Ariane Düx
JHJulia Hinzmann
Julia Hinzmann
NMN' Faly Magassouba
N' Faly Magassouba

13 April 2017 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
ESEtienne Simon-Loriere
Etienne Simon-Loriere
OFOusmane Faye
Ousmane Faye
MPMatthieu Prot
Matthieu Prot
ICIsabelle Casademont
Isabelle Casademont
GFGamou Fall
Gamou Fall
ASAmadou A. Sall
Amadou A. Sall
Japanese encephalitis virus and yellow fever virus are mosquito-borne flaviviruses that circulate in disjunct geographic areas with different mosquito vectors. Japanese encephalitis is endemic to most of Asia and the Western Pacific, whereas yellow fever occurs in tropical areas of Africa and South America. Both viruses lead to a wide spectrum of disease severities that include asymptomatic infection and mild illness with influenza-like symptoms. However, severe yellow fever disease can be fatal in 20 to 60% of cases,1 whereas symptomatic Japanese encephalitis virus can progress to severe encephalitis, with case fatality rates of up to 30%. Survivors often have long-term neuropsychological sequelae.2

1 April 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PMPlacide Kingebeni Mbala
Placide Kingebeni Mbala
CPCatherine Pratt
Catherine Pratt
MMMbusa Mutafali-Ruffin
Mbusa Mutafali-Ruffin
MPMatthias G. Pauthner
Matthias G. Pauthner
FBFaustin Bile
Faustin Bile
JTJean-Jacques Muyembe Tamfum
Jean-Jacques Muyembe Tamfum
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)

20 January 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
Ahmed Abd El WahedAhmed Abd El Wahed
Ahmed Abd El Wahed
PPPranav Patel
Pranav Patel
MMMelanie Maier
Melanie Maier
CPCorinna Pietsch
Corinna Pietsch
DRDana Rüster
Dana Rüster
Manfred WeidmannManfred Weidmann
Manfred Weidmann

10 January 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Giulia MencattelliGiulia Mencattelli
Giulia Mencattelli
MNMarie Henriette Dior Ndione
Marie Henriette Dior Ndione
Roberto RosàRoberto Rosà
Roberto Rosà
GMGiovanni Marini
Giovanni Marini
CDCheikh Tidiane Diagne
Cheikh Tidiane Diagne
Annapaola RizzoliAnnapaola Rizzoli
Annapaola Rizzoli
Background: West Nile virus is a mosquito-borne flavivirus which has been posing continuous challenges to public health worldwide due to the identification of new lineages and clades and its ability to invade and establish in an increasing number of countries. Its current distribution, genetic variability, ecology, and epidemiological pattern in the African continent are only partially known despite the general consensus on the urgency to obtain such information for quantifying the actual disease burden in Africa other than to predict future threats at global scale.Methodology and principal findings: References were searched in PubMed and Google Scholar electronic databases on January 21, 2020, using selected keywords, without language and date restriction. Additional manual searches of reference list were carried out. Further references have been later added accordingly to experts’ opinion. We included 153 scientific papers published between 1940 and 2021.This review highlights: (i) the co-circulation of WNV-lineages 1, 2, and 8 in the African continent; (ii) the presence of diverse WNV competent vectors in Africa, mainly belonging to theCulexgenus; (iii) the lack of vector competence studies for several other mosquito species found naturally infected with WNV in Africa; (iv) the need of more competence studies to be addressed on ticks; (iv) evidence of circulation of WNV among humans, animals and vectors in at least 28 Countries; (v) the lack of knowledge on the epidemiological situation of WNV for 19 Countries and (vii) the importance of carrying out specific serological surveys in order to avoid possible bias on WNV circulation in Africa.Conclusions: This study provides the state of art on WNV investigation carried out in Africa, highlighting several knowledge gaps regarding i) the current WNV distribution and genetic diversity, ii) its ecology and transmission chains including the role of different arthropods and vertebrate species as competent reservoirs, and iii) the real disease burden for humans and animals. This review highlights the needs for further research and coordinated surveillance efforts on WNV in Africa.

18 January 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
OFOusmane Faye
Ousmane Faye
CPCatherine B Pratt
Catherine B Pratt
Martin FAYEMartin FAYE
Martin FAYE
GFGamou Fall
Gamou Fall
JCJoseph A Chitty
Joseph A Chitty
CIChikwe Ihekweazu
Chikwe Ihekweazu